0 0 0 0 0 0 0 0
Sign Up Today X
Thanks for submitting the form.
Stockreport

Regeneron Tops Q1 Estimates on Dupixent Momentum [Yahoo! Finance]

Regeneron Pharmaceuticals, Inc. (REGN)  More Company Research Source: Yahoo! Finance
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.regeneron.com
Adjusted earnings per share came in at $9.47, ahead of the analyst consensus of $8.97 by $0.50. Revenue reached $3.6 billion, up 19% year over year from $3.0 billion and above the $3.48 billion estimate. Shares rose 1.4% following the announcement. Global net sales of Dupixent, recorded by Sanofi, climbed 33% to $4.9 billion, driving a 36% increase in collaboration revenue to $1.6 billion. In contrast, combined U.S. net sales of EYLEA HD and EYLEA declined 10% to $941 million. EYLEA HD sales rose 52% to $468 million, while legacy EYLEA revenue dropped 36% to $473 million due to competitive pressures and ongoing patient transitions to the newer formulation. “In the first quarter of this year, we were able to achieve strong double-digit growth on both the top and bottom line while continuing to invest significant resources in our portfolio of nearly 50 product candidates in clinical development,” said Leonard S. Schleifer. The company's GAAP gross margin on net product sales de [Read more]
IMPACT SNAPSHOT EVENT TIME: REGN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
REGN alerts
from News Quantified
REGN
NEWS
REGN
Earnings
REGN
Analyst Actions
REGN
SEC Filings
Stockreport

Regeneron Tops Q1 Estimates on Dupixent Momentum [Yahoo! Finance]

Regeneron Pharmaceuticals, Inc.  (REGN) 
More Company Research Source: Yahoo! Finance
Last regeneron pharmaceuticals, inc. earnings: 2/6 06:30 am Check Earnings Report
US:NASDAQ Investor Relations: investor.regeneron.com
Adjusted earnings per share came in at $9.47, ahead of the analyst consensus of $8.97 by $0.50. Revenue reached $3.6 billion, up 19% year over year from $3.0 billion and above the $3.48 billion estimate. Shares rose 1.4% following the announcement. Global net sales of Dupixent, recorded by Sanofi, climbed 33% to $4.9 billion, driving a 36% increase in collaboration revenue to $1.6 billion. In contrast, combined U.S. net sales of EYLEA HD and EYLEA declined 10% to $941 million. EYLEA HD sales rose 52% to $468 million, while legacy EYLEA revenue dropped 36% to $473 million due to competitive pressures and ongoing patient transitions to the newer formulation. “In the first quarter of this year, we were able to achieve strong double-digit growth on both the top and bottom line while continuing to invest significant resources in our portfolio of nearly 50 product candidates in clinical development,” said Leonard S. Schleifer. The company's GAAP gross margin on net product sales de [Read more]
IMPACT SNAPSHOT
EVENT TIME:
REGN
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Don't Miss Out On The Next BIG Stock Move
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
 POST NEWS RANGE
%
PRICE CHANGE
PRICE CHANGE PERCENTAGE
S&P 500 (SPX)
%
 VOLUME RATIO
%
VOLUME (SHARES)
TICKS
AVG SHARES PER TRADE
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS